SCHEMBL21146727

SCHEMBL21146727

CC(=O)NC1C(OC2OC(CO)C(O)C(O)C2O)C(O)C(CO)OC1C(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 5/20 0.56
▸ LGALS8 O00214 1/20 0.56
▸ LGALS4 P56470 1/20 0.56
▸ CD69 Q07108 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ MAPK1 P28482 2/20 0.49
▸ CHIA Q9BZP6 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ FGF1 P05230 1/20 0.43
▸ FGF2 P09038 1/20 0.43
▸ VEGFA P15692 1/20 0.43
▸ HPSE Q9Y251 1/20 0.43
▸ LGALS1 P09382 1/20 0.43
▸ LGALS7; LGALS7B P47929 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13663191 0.93 LGALS3 (0.62) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663185 0.90 LGALS3 (0.60) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663193 0.90 LGALS3 (0.52) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663197 0.90 LGALS3 (0.62) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL20021737 0.90 LGALS3 (0.47) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663194 0.88 LGALS8 (0.48) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663196 0.88 CD69 (0.59) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL18300844 0.87 LGALS3 (0.60) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL20998797 0.86 LGALS3 (0.55) LGALS3LGALS8LGALS4CD69ALDH1A1
SCHEMBL13663186 0.86 LGALS3 (0.56) LGALS3LGALS8LGALS4CD69ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190211099-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH SIGLEC-9 ACTIVITY MODULATORS KING'S COLLEGE LONDON (GB) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211099-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER WITH SIGLEC-9 ACTIVITY MODULATORS SIGLEC9, SIGLEC7, MUC1 LGALS3 18/4885LGALS8 38/4885LGALS4 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback